Aspirin Resistance in Systemic Lupus Erythematosus (SLE)

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study examine whether patients with lupus respond to aspirin , and if not, if that is related to inflammation. We examine the ability of aspirin to inhibit the production of thromboxane in patients with lupus and controls and see if aspirin insensitive thromboxane production is inhibited by meloxicam.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Aspirin; Meloxicam

Criteria

Inclusion Criteria:

• Written Informed consent.

• Age >18 yrs.

• SLE meeting ACR criteria {Tan, Cohen, et al. 1982 1482 /id} for at least 6 months.(SLE group)

• Stable disease activity as evidenced by no change in immunosuppressive therapy in the past 1 month.

• If female of childbearing potential must use an effective method of birth control

Exclusion criteria.

• Renal disease (creatinine >1.5 mg/dL, dialysis, 2+ or more proteinuria)

• Previous or current history of peptic ulcer disease or gastrointestinal bleed.

• Previous or current thromboembolic or ischemic cardiovascular event (stroke, myocardial infarction, angina) - can do aspirin part of study.

• Currently taking an anticoagulant or antiplatelet agent (besides aspirin).

• Thrombocytopenia (platelet count <135,000)

• Pregnancy

• Allergy to aspirin, NSAIDs

• NSAIDs in the previous week